Anti-Group B Streptococcus Glycan-Conjugate Vaccines Using Pilus Protein GBS80 As Carrier and Antigen: Comparing Lysine and Tyrosine-directed Conjugation

ACS Chemical Biology

Volumn 10, Issue 7, 2015, Pages 1737-1746

  Nilo, Alberto ^a   Morelli, Laura ^a   Passalacqua, Irene ^a   Brogioni, Barbara ^a   Allan, Martin ^b   Carboni, Filippo ^a   Pezzicoli, Alfredo ^a   Zerbini, Francesca ^a   Maione, Domenico ^a   Fabbrini, Monica ^a   Romano, Maria Rosaria ^a   Hu, Qi Ying ^b   Margarit, Immaculada ^a   Berti, Francesco ^a   Adamo, Roberto ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL PROTEIN; DIPHTHERIA TOXOID CRM197; GBS80 PROTEIN; GLYCAN; GLYCOCONJUGATE; STREPTOCOCCUS VACCINE; TYROSINE; UNCLASSIFIED DRUG; CAPSULAR POLYSACCHARIDE, STREPTOCOCCAL GROUP B TYPE II; LYSINE; VACCINE;

AMINATION; ANTIBODY RESPONSE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM PILUS; CONJUGATION; CONTROLLED STUDY; CYCLOADDITION; FEMALE; GLYCOCONJUGATION; GROUP B STREPTOCOCCAL INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; MOUSE; MURINAE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; VACCINATION; ANIMAL; BACTERIAL CAPSULE; CELL LINE; CHEMISTRY; FIMBRIA; HUMAN; IMMUNOLOGY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

BACTERIA (MICROORGANISMS); MURINAE; MUS; POSIBACTERIA; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS SP. 'GROUP B';

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL CAPSULES; BACTERIAL PROTEINS; CELL LINE; FEMALE; FIMBRIAE, BACTERIAL; GLYCOCONJUGATES; HUMANS; LYSINE; MICE; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS AGALACTIAE; TYROSINE; VACCINATION; VACCINES, CONJUGATE;

EID: 84937134192     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/acschembio.5b00247     Document Type: Article

References (44)

1. Baker, C. J., Rench, M. A., Edwards, M. S., Carpenter, R. J., Hays, B. M., and Kasper, D. L. (1988) Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus N. Engl. J. Med. 319, 1180-1185
2. Harrison, L. H., Elliot, J. A., Dwyer, D. M., Libonati, J. P., Ferrieri, P., Billmann, L., and A, S. (1998) Serotype Distribution of Invasive Group B Streptococcal Isolates in Maryland: Implications for Vaccine Formulation J. Infect. Dis. 177, 998-1002
3. Chen, V. L., Fikri, Y. A., and Kasper, D. L. (2013) A maternal vaccine against group B Streptococcus: Past, present, and future Vaccine 31, 13-19
4. Munoz, F. M. and Ferrieri, P. (2013) Group B Streptococcus vaccination in pregnancy: Moving toward a global maternal immunization program Vaccine 31, 46-52
5. Lancefield, R. C. (1934) A serological differentiation of specific types of bovine hemolytic streptococci (Group B) J. Exp. Med. 59, 441-458
6. Lancefield, R. C. (1938) Two serological types of Group B hemolytic streptococci with related, but not identical, type-specific substances J. Exp. Med. 67, 25-40
7. Lancefield, R. C., McCarty, M., and Everly, W. N. (1975) Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens J. Exp. Med. 142, 165-179
8. Zalenik, D. F., Rench, M. A., Hillier, S., Krohn, M. A., Platt, R., Lee, M. T., Flores, A. E., Ferrieri, P., and Baker, C. J. (2000) Invasive disease due to Group B Streptococcus in pregnant women and neonates from diverse population groups Clin. Infect. Dis. 30, 276-282
9. Lancaster, L., Saydam, M., Markey, K., Ho, M. M., and Mawas, F. (2011) Immunogenicity and physico-chemical characterisation of a candidate conjugate vaccine against group B streptococcus serotypes Ia, Ib and III Vaccine 29, 3213-3242
10. Baker, C. J., Edwards, M. S., and Kasper, D. L. (1981) Role of antibody to native type-III polysaccharide of Group-B Streptococcus in infant infection Pediatrics 68, 544-549
11. Avci, F. Y. and Kasper, D. L. (2010) How bacterial carbohydrates influence the adaptive immune system Annu. Rev. Immunol. 28, 107-130
12. Avci, F. Y., Li, X., Tsuji, M., and Kasper, D. L. (2012) A novel mechanism for glycoconjugate vaccine activation of the adaptive immune system Nat. Med. 17, 1602-1609
13. Paoletti, L. C., Wessels, M. R., Michon, F., Difabio, J., Jennings, H. J., and Kasper, D. L. (1992) Group-B Streptococcus type-II polysaccharide-Tetanus Toxoid conjugate vaccine Infect. Immun. 60, 4009-4014
14. Wessels, M. R., Paoletti, L. C., Rodewald, A. K., Michon, F., DiFabio, J., Jennings, H. J., and Kasper, D. L. (1993) Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine Infect. Immun. 61, 4760-4766
15. Wessels, M. R., Paoletti, L. C., Pinel, J., and Kasper, D. L. (1995) Immunogenicity and Protective Activity in animals of a Type-V Group-B Streptococcal polysaccharide Tetanus Toxoid conjugate vaccine J. Infect. Dis. 171, 879-884
16. Paoletti, L. C., Peterson, D. L., Legmann, R., and Collier, R. J. (2001) Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen Vaccine 20, 370-376
17. Madhi, S. A., Dangor, Z., Heath, P. T., Schrag, S., Izu, A., Sobanjo-ter Meulen, A., and Dull, P. M. (2013) Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants Vaccine 31, 52-57
18. Le Doare, K. and Heath, P. T. (2013) An overview of global GBS epidemiology Vaccine 31, 7-12
19. Rappuoli, R. (2000) Reverse vaccinology Curr. Opin. Microbiol. 3, 445-450
20. Rappuoli, R. and Serruto, D. (2006) Post-genomic vaccine development FEBS Lett. 580, 2985-2992
21. Maione, D., Margarit, I., Rinaudo, C. D., Masignani, V., Mora, M., Scarselli, M., Tettelin, H., Brettoni, C., Iacobini, E. T., Rosini, R., D'Agostino, N., Miorin, L., Buccato, S., Mariani, M., Galli, G., Nogarotto, R., Nardi Dei, V., Vegni, F., Fraser, C., Mancuso, G., Teti, G., Madoff, L. C., Paoletti, L. C., Rappuoli, R., Kasper, D. L., Telford, J. L., and Grandi, G. (2005) Identification of a universal Group B streptococcus vaccine by multiple genome screen Science 309, 148-150
22. Margarit, I., Rinaudo, C. D., Galeotti, C. L., Maione, D., Ghezzo, C., Buttazzoni, E., Rosini, R., Runci, Y., Mora, M., Buccato, S., Pagani, M., Tresoldi, E., Berardi, A., Creti, R., Baker, C. J., Telford, J. L., and Grandi, G. (2009) Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm J. Infect. Dis. 199, 108-115
23. Dagan, R., Poolman, J., and Siegrist, C. (2010) Glycoconjugate vaccines and immune interference: A review Vaccine 28, 5513-5524
24. Santamaria, R., Goulart, C., Perciani, C. T., Barazzone, G. C., Carvalho, R., Goncalves, V. M., Leite, L. C. C., and Tanizaki, M. M. (2011) Humoral immune response of a pneumococcal conjugate vaccine: Capsular polysaccharide serotype 14-Lysine modified PspA Vaccine 29, 8689-8695
25. Berti, F. and Adamo, R. (2013) Recent mechanistic insights on glycoconjugate vaccines and future perspectives ACS Chem. Biol. 8, 1653-1663
26. Boutureira, O. and Bernardes, G. J. L. (2015) Advances in chemical protein modification Chem. Rev. 10.1021/cr500399p
27. Adamo, R., Nilo, A., Castagner, B., Boutureira, O., Berti, F., and Bernardes, G. J. L. (2013) Synthetically defined glycoprotein vaccines: current status and future directions Chem. Sci. 4, 2995-3008
28. Hu, Q., Allan, M., Adamo, R., Quinn, D., Zhai, H., Wu, G., Clark, K., Zhou, J., Ortiz, S., Wang, B., Danieli, E., Crotti, S., Tontini, M., Brogioni, G., and Berti, F. (2013) Synthesis of a well-defined glycoconjugate vaccine by a tyrosine-selective conjugation strategy Chem. Sci. 4, 3827-3832
29. Baskin, J. M., Prescher, J. A., Laughlin, S. T., Agard, N. J., Chang, P. V., Miller, I. A., Lo, A., Codelli, J. A., and Bertozzi, C. R. (2007) Copper-free click chemistry for dynamic in vivo imaging Proc. Natl. Ac. Sci. U. S. A. 104, 16793-16797
30. Jewett, J. C. and Bertozzi, C. R. (2010) Cu-free click cycloaddition reactions in chemical biology Chem. Soc. Rev. 39, 1272-1279
31. Adamo, R., Allan, M., Berti, F., Danieli, E., and Hu, Q. Tyrosine ligation process and crosslinking agents used to form tyrosine-contg. polypeptide conjugates for raising an immune response in a mammal, PCT Int. Appl. WO 2013009564A1, 1/17/2013.
32. Nilo, A., Allan, M., Brogioni, B., Proietti, D., Cattaneo, V., Crotti, S., Sokup, S., Zhai, H., Margarit, I., Berti, F., Hu, Q., and Adamo, R. (2014) Tyrosine-directed conjugation of large glycans to proteins via copper-free click chemistry Bioconj. Chem. 10.1021/bc500438h
33. Pinto, V. and Berti, B. (2014) Exploring the Group B Streptococcus capsular polysaccharides: The structural diversity provides the basis for development of NMR-based identity assays J. Phar. Biomed. Anal. 98, 9-15
34. Vengadesan, K., Ma, X., Dwivedi, P., Ton-That, H., and Narayanan, S. V. L (2010) Purification, crystallization and halide phasing of a Streptococcus agalactiae backbone pilin GBS80 fragment Acta Crystallogr. F66, 1666-1669
35. Michon, F., Uitz, C., Sarkar, A., D'Ambra, A. J., Laude-Sharp, M., and Fusco, P. C. (2006) Group B Streptococcal type II and III conjugate vaccines: Physicochemical properties that influence immunogenicity Clin. Vacc. Immunol. 13, 936-943
36. 197, diphtheria toxoid and tetanus toxoidas protein carriers for meningococcal glycoconjugate vaccines Vaccine 31, 4827-4833
37. Guttormsen, H., Liu, Y., and Paoletti, L. C. (2008) Functional activity of antisera to group B streptococcal conjugate vaccines measured with an opsonophagocytosis assay and HL-60 effector cells Hum. Vacc. 4, 370-374
38. Brigtsen, A. K., Kasper, D. L., Baker, C. J., Jennings, H., Jr., and Guttormsen, H. (2002) Induction of Cross-Reactive Antibodies by Immunization of Healthy Adults with Types Ia and Ib Group B Streptococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccines 185, 1277-1284
39. Shigeoka, A. O., Jensen, C. L., Pincus, S. H., and Hill, H. R. (1984) Absolute requirement for complement in monoclonal IgM antibody-mediated protection against experimental infection with type III group B streptococci J. Infect Dis. 150, 63-70
40. Yin, Z., Nguyen, H. G., Chowdhury, S., Bentley, P., Bruckman, M. A., Miermont, A., Gildersleeve, J. C., Wang, Q., and Huang, X. (2012) Tobacco mosaic virus as a new carrier for tumor associated carbohydrate antigens Bioconjugate Chem. 23, 1694-1703
41. Buskas, T., Li, Y., and Boons, G. J. (2004) The immunogenicity of the tumor-associated antigen Lewisy may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein Chemistry 10, 3517-3524
42. Adamo, R., Hu, Q., Torosantucci, A., Crotti, S., Brogioni, G., Allan, M., Chiani, P., Bromuro, C., Quinn, D., Tontini, M., and Berti, F. (2014) Deciphering the structure-immunogenicity relationship of anti-Candida glycoconjugate vaccines Chem. Sci. 5, 4302-4311
43. Wessels, M. R., Paoletti, L. C., Kasper, D. L., DiFabio, J., Michon, F., Holme, K., and Jennings, H., Jr. (1990) Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III Group B Streptococcus J. Clin. Invest. 86, 1428-1433
44. Costantino, P., Norelli, F., Giannozzi, A., D'Ascenzi, S., Bartoloni, A., Kaur, S., Tang, D., Seid, R., Viti, S., Paffetti, R., Bigio, M., Pennatini, C., Averani, G., Guarnieri, V., Gallo, E., Ravenscroft, N., Lazzeroni, C., Rappuoli, R., and Ceccarini, C. (1999) Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines Vaccine 17, 1251-1263